Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Damon on Allogeneic Stem Cell Transplant in AML

October 30th 2018

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses allogeneic stem cell transplant (ASCT) in the treatment of patients with acute myeloid leukemia (AML).

Dr. Martin on Transplant and Maintenance for Patients With High-Risk Myeloma

October 30th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses transplant and maintenance for the treatment of patients with high-risk multiple myeloma.

Emerging Agents, TKI Discontinuation Focal Points of CML Research

October 29th 2018

Neil P. Shah, MD, PhD, discusses emerging agents and the tyrosine kinase inhibitor discontinuation approach in the landscape of chronic myeloid leukemia.

FDA Grants Priority Review to Ruxolitinib for GVHD

October 26th 2018

The FDA has granted a priority review designation to a supplemental new drug application for ruxolitinib (Jakafi) for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids.

Treatment Regimens to Be Refined in Hodgkin Lymphoma

October 26th 2018

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

Dr. Bartlett on Treatment Regimens for Patients With Hodgkin Lymphoma

October 26th 2018

Nancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.

Genomic Breakthroughs Offer Hope for New Strategies in AML

October 23rd 2018

Hetty Carraway, MD, highlights ongoing genomic research in acute myeloid leukemia, as well as recent therapeutic advances in the field.

Dr. Uy on Therapy Selection in Acute Myeloid Leukemia

October 23rd 2018

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).

Dr. Vij on the Optimal Induction Therapy in Multiple Myeloma

October 20th 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Dr. Oh on the Development of JAK Inhibitors in Myelofibrosis

October 20th 2018

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

Expert Breaks Down Diagnosis and Treatment of Classical MPNs

October 19th 2018

Vivian G. Oehler, MD, discusses the diagnosis, risk prognostication and therapeutic strategies for polycythemia vera, essential thrombocytopenia, and myelofibrosis.

Japanese Approval Sought for Quizartinib in FLT3-ITD+ AML

October 18th 2018

A new drug application has been submitted to Japan's Ministry of Health, Labor and Welfare for quizartinib for the treatment of adult patients with FLT3-ITD–positive acute myeloid leukemia.

Dr. Damon on Drug Development in AML

October 17th 2018

Dr. Fakhri on the Use of Carfilzomib in Multiple Myeloma

October 16th 2018

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

Dr. Martin on Autologous Stem Cell Transplant in Multiple Myeloma

October 12th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Dr. Radich on Compliance to NCCN Guidelines in CML

October 12th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Expert Highlights FLT3 Inhibitors in AML

October 11th 2018

Mary-Beth Percival, MD, discusses the ongoing development of FLT3 inhibitors and other current research in patients with AML.

Dr. Valent on MRD Negativity in Multiple Myeloma

October 11th 2018

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Dr. Carraway on Predisposition to Acute Myeloid Leukemia

October 11th 2018

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).

Targeted Agents Beyond Ruxolitinib Necessary in Evolving MPN Paradigm

October 11th 2018

Aaron Gerds, MD, discusses the activity and drawbacks with current systemic agents in myeloproliferative neoplasms.